For example, Rhode Island and Louisiana administered mAbs to the highest proportion of non-hospitalized patients with COVID-19 (24.9% and 21.2%), while Alaska and Washington administered the lowest proportion (1.1% and 0.7%). In addition, there were significant differences among states when it came to mAb treatment. The researchers also found that Blacks were less likely to receive mAbs than whites-6.2% versus 7.4%.
The likelihood of receiving mAbs was higher among those with fewer chronic conditions-23.2% of those with no chronic conditions received mAbs, versus 6.3%, 6.0%, and 4.7% of those with 1-3, 4-5, and 6 or more chronic conditions, respectively. They found that, among Medicare beneficiaries who weren’t hospitalized or who didn’t pass away within seven days of their diagnosis, only 7.2% received mAb therapy. They looked at data from more than 1.9 million Medicare beneficiaries who had been diagnosed with COVID-19 between November 2020 and August 2021, and compared rates of receiving mAbs by age, sex, race and ethnicity, region, and number of chronic conditions. The researchers wanted to learn how the limited supply of mAb therapy was allocated to patients at highest risk for severe disease. Federal guidelines prioritize patients at higher risk of being hospitalized or dying from COVID-19, including older people and those with chronic conditions. But during the pandemic, mAbs have been in short supply. Monoclonal antibodies are very effective at treating mild to moderate COVID-19 infection among non-hospitalized patients. Unfortunately, our federal and state system for distributing these drugs has failed our most vulnerable patients,” said Michael Barnett, assistant professor of health policy and management at Harvard Chan School and lead author of the study. “Monoclonal antibodies should first go to patients at the highest risk of death from COVID-19, but the opposite happened-the healthiest patients were the most likely to get treatment.
The analysis will be published online Februin JAMA. states, according to new research co-authored by researchers from Harvard T.H. For immediate release: Friday, February 4, 2022īoston, MA – People over age 65 at the highest risk for severe COVID-19 have often been the least likely to receive monoclonal antibodies (mAbs)-a highly effective treatment for the disease-both across and within U.S.
0 kommentar(er)
